Stephan Cote - Reunion Neuroscience Head Quality
| REUNDelisted Stock | USD 1.12 0.01 0.90% |
Insider
Stephan Cote is Head Quality of Reunion Neuroscience
| Web | https://www.fieldtriphealth.com |
Reunion Neuroscience Management Efficiency
The company has return on total asset (ROA) of (0.2651) % which means that it has lost $0.2651 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8635) %, meaning that it created substantial loss on money invested by shareholders. Reunion Neuroscience's management efficiency ratios could be used to measure how well Reunion Neuroscience manages its routine affairs as well as how well it operates its assets and liabilities.Reunion Neuroscience currently holds 3.37 M in liabilities. Reunion Neuroscience has a current ratio of 46.79, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Reunion Neuroscience's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| James Collins | Senti Biosciences | 58 | |
| Clive Brown | Oxford Nanopore Technologies | N/A | |
| Philip Lee | Senti Biosciences | 42 | |
| Michael Beck | OKYO Pharma Ltd | 67 | |
| Darlene Noci | Nuvalent | 46 | |
| Sara Le | Oxford Nanopore Technologies | N/A | |
| Stephen Toor | Pharming Group NV | 52 | |
| John Schoellerman | Oxford Nanopore Technologies | N/A | |
| Jeff Fensterer | Accustem Sciences | 44 | |
| Joe Flanagan | Accustem Sciences | 49 | |
| Wilson Wong | Senti Biosciences | N/A | |
| Susan Kahlert | Senti Biosciences | N/A | |
| Keeren Shah | OKYO Pharma Ltd | 49 | |
| Pr Bayley | Oxford Nanopore Technologies | N/A | |
| MBA MD | Pharming Group NV | 63 | |
| Craig Esq | Cingulate | 51 | |
| Rajkumar Patil | OKYO Pharma Ltd | 65 | |
| Gordon Sanghera | Oxford Nanopore Technologies | N/A | |
| Anurag Relan | Pharming Group NV | 51 | |
| Deborah Knobelman | Senti Biosciences | 50 | |
| Jordan Herman | Oxford Nanopore Technologies | N/A | |
Management Performance
| Return On Equity | -0.86 | |||
| Return On Asset | -0.27 |
Reunion Neuroscience Leadership Team
Elected by the shareholders, the Reunion Neuroscience's board of directors comprises two types of representatives: Reunion Neuroscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Reunion. The board's role is to monitor Reunion Neuroscience's management team and ensure that shareholders' interests are well served. Reunion Neuroscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Reunion Neuroscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, VP Director | ||
| Nathan BSc, Chief Officer | ||
| Stephan Cote, Head Quality | ||
| Hannan Fleiman, CoFounder Director | ||
| Mujeeb Jafferi, COFounder COO | ||
| Edward CPA, Chief Officer | ||
| Vicki Reed, Chief Officer | ||
| Curtis Weber, Gen Sec | ||
| JD Esq, CEO Pres | ||
| Matt Emmer, Director Devel |
Reunion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Reunion Neuroscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.86 | |||
| Return On Asset | -0.27 | |||
| Current Valuation | (13.96 M) | |||
| Shares Outstanding | 11.72 M | |||
| Shares Owned By Insiders | 34.39 % | |||
| Shares Owned By Institutions | 50.65 % | |||
| Number Of Shares Shorted | 114.9 K | |||
| Price To Book | 0.49 X | |||
| Price To Sales | 2.80 X | |||
| Gross Profit | (4.29 M) |
Pair Trading with Reunion Neuroscience
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Reunion Neuroscience position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Reunion Neuroscience will appreciate offsetting losses from the drop in the long position's value.Moving against Reunion Stock
| 0.77 | REGN | Regeneron Pharmaceuticals | PairCorr |
| 0.72 | AULT | Ault Alliance Symbol Change | PairCorr |
| 0.71 | QSAM | Qsam Biosciences | PairCorr |
| 0.7 | NVO | Novo Nordisk AS | PairCorr |
| 0.69 | NONOF | Novo Nordisk AS | PairCorr |
The ability to find closely correlated positions to Reunion Neuroscience could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Reunion Neuroscience when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Reunion Neuroscience - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Reunion Neuroscience to buy it.
The correlation of Reunion Neuroscience is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Reunion Neuroscience moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Reunion Neuroscience moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Reunion Neuroscience can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Reunion Stock
If you are still planning to invest in Reunion Neuroscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reunion Neuroscience's history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |